Moreover, inhibition of Akt phosphorylation nullifies the directional response of EGF(−)/iEF(+) breast cancer cell motility but confers additional inhibition for EGF(+)/iEF(+)—showing the potential therapeutic value of iEFs when combined with anti-cancer drugs. The gene discussed is EGF; the disease is breast carcinoma.